Aviva Systems Biology's founding team has extensive backgrounds in biotechnology development and commercialization. Since 2002, they have guided Aviva into becoming one of the premier antibody manufacturing organizations in its respective industry.

Peter Jiang, M.D. - President & Chief Executive Officer

Dr. Jiang brings a vast amount of knowledge and experience in biotechnology and management to Aviva from more than fifteen years of experience in the pharmaceutical and biotech industries. Dr. Jiang has previously served as Vice President of Operations in Aviva in San Diego and President of Aviva in Beijing. Before joining Aviva, Dr. Jiang managed Tang Pharmaceuticals in China as General Manager from 1999 to 2007. Prior to that, Dr. Jiang served as assistant professor in the Department of Medicine at Northwestern University. Dr. Jiang holds a M.D. degree in Pediatrics.

Matt Landry - Vice President of Marketing and Sales

Mr. Landry brings expertise in marketing, sales, business development, and operations to the Aviva team from over 10 years of experience in the research and diagnostic markets. Mr. Landry was previously the Senior Vice President of Marketing and Sales at GenWay Biotech, where he established multiple commercialization platforms. Prior to GenWay, he focused on sales at Stratagene (acquired by Agilent) and USB Corporation (acquired by Affymetrix). Mr. Landry holds a B.S. in Biotechnology with an emphasis in microbiology, viticulture and enology from University of California at Davis.

Husheng Zhang, Ph. D.- Vice President of Aviva Systems Biology Beijing

Dr. Zhang is responsible for polyclonal antibody production, quality control, technical support and R&D in Aviva Systems Biology Beijing. He has over seven years of molecular biology experience and polyclonal antibody production experience. He is a graduate of the prestigious Cancer Institute, Chinese Academy of Medical Sciences.